Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy

doi:10.1128/AAC.02174-16

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 保健營養系(所) > 期刊論文 > Item 310902800/31592

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31592

標題:	Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy
作者:	Lee, Ching-Chi Wang, Jiun-Ling Lee, Chung-Hsun Hsieh, Chih-Chia Hung, Yuan-Pin Hong, Ming-Yuan Tang, Hung-Jen Ko, Wen-Chien
貢獻者:	Madou Sin Lau Hosp, Dept Internal Med, Div Crit Care Med Chang Jung Christian Univ, Grad Inst Med Sci, Coll Hlth Sci Natl Cheng Kung Univ, Dept Internal Med,Natl Cheng Kung Univ Hosp, Coll Med Natl Cheng Kung Univ, Dept Med, Coll Med Natl Cheng Kung Univ, Dept Emergency Med,Natl Cheng Kung Univ Hosp, Coll Med Minist Hlth & Welf, Dept Internal Med, Tainan Hosp Chi Mei Med Ctr, Dept Med Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
關鍵字:	fluoroquinolone third-generation cephalosporin empirical therapy community onset bacteremia defervescence
日期:	2017-02
上傳時間:	2018-11-30 15:49:28 (UTC+8)
出版者:	Amer Soc Microbiology
摘要:	Both fluoroquinolones (FQs) and third-generation cephalosporins (3rd-GCs) are commonly prescribed to treat bloodstream infections, but comparative efficacies between them were rarely studied. Demographics and clinical characteristics of 733 adults with polymicrobial or monomicrobial community-onset bacteremia empirically treated by an appropriate FQ (n = 87) or 3rd-GC (n = 646) were compared. A critical illness (respectively, 8.0% versus 19.0%; P = 0.01), an initial syndrome with severe sepsis (33.3% versus 50.3%; P = 0.003), or a fatal outcome at 28 days (4.6% versus 10.5%; P = 0.08) was less common in the FQ group. A total of 645 (88.0%) patients were febrile at initial presentation, and the FQ group with (FQ group versus 3rd-GC group, respectively, 7.6 days versus 12.0 days; P = 0.04) and without (3.8 days versus 5.4 days; P = 0.001) a critical illness had a shorter time to defervescence than the 3rd-GC group. By the propensity scores, 87 patients with appropriate FQ therapy were matched with 435 treated by 3rd-GC therapy at a ratio of 1: 5, and there were no significant differences in terms of bacteremia severity, comorbidity severity, major comorbidities, causative microorganisms, and bacteremia sources between groups. Moreover, crude mortality rates at 28 days (FQ group versus 3rd-GC group, respectively, 4.6% versus 7.8%; P = 0.29) did not differ significantly. However, the time to defervescence was shorter in the FQ group (4.2 +/- 3.6 versus 6.2 +/- 7.6 days; P = 0.001). Conclusively in the adults with community-onset bacteremia, appropriate empirical FQ therapy was related to shorter time to defervescence than with 3rd-GC therapy, at least for those without a critical illness.
關聯:	Antimicrobial Agents and Chemotherapy, v.61, n.2, e02174-16
顯示於類別:	[保健營養系(所) ] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
e02174-16.full.pdf		605Kb	Adobe PDF	0	檢視/開啟
index.html		0Kb	HTML	1318	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....